Stock comparison
Alkermes
Halozyme Therapeutics
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ALKS
Alkermes
Market cap
$6.13B
Sector
Healthcare
HALO
Halozyme Therapeutics
Market cap
$8.1B
Sector
Healthcare
Overall winner
Halozyme Therapeutics HALO
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ALKS | HALO | Winner |
|---|---|---|---|
| Warren Buffett | 65C | 79B | HALO |
| Benjamin Graham | 74D | 83A | HALO |
| Philip Fisher | 58C | 65B | HALO |
| Peter Lynch | 44D | 53D | HALO |
| Joel Greenblatt | 51D | 40D | ALKS |
| Charlie Munger | 62D | 80C | HALO |
| Terry Smith | 60D | 84A | HALO |
Side-by-side metrics
| Metric | ALKS | HALO |
|---|---|---|
| Market cap | $6.13B | $8.1B |
| P/E (TTM) | 41.7x | 24.0x |
| EV/EBIT | 30.0x | 10.2x |
| ROIC (TTM) | 3.89% | 23.65% |
| Gross margin | 86.63% | 81.24% |
| Net margin | 9.78% | 23.13% |
| Revenue CAGR 5y | 5.89% | 33.23% |
| EPS CAGR 5y | - | -1.98% |
| Debt / Equity | 0.9x | 1.0x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ALKS leads on
- Gross margin86.63%vs 81.24%+6%
HALO leads on
- ROIC (TTM)23.65%vs 3.89%+84%
- Revenue CAGR 5y33.23%vs 5.89%+82%
- EV/EBIT10.2xvs 30.0x+66%
- Net margin23.13%vs 9.78%+58%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.